Member Info for daveycaferacer

Look under Share Statistics section, although I think the data is only updated monthly
https://finance.yahoo.com/quote/TLSA/key-statistics?p=TLSA

Volume 6,606,456
Avg. Volume 390,353
The numbers speak for themselves

BGNE's mcap is now over $28bn which shows that it's possible to grow tenfold in 4 years

I hope we will follow a similar trajectory at some point again

Generally with US Treasury yields so low and Congress just about to sign of on another massive stimulus, most of that money will end up in assets, and that means equities. The total value of the stimulus is 25% of U.S. GDP and that money needed to find a home. Because of that equities probably have much longer to run yet.

The NASDAQ Biotech index is up over 33% y-on-y and healthcare is up there with Tech Growth stocks.

I mean I completely AGREE ;o-/

"Quickest way to lose money Is keep jumping ship"

I complete disagree, it's a known fact that the majority of traders lose money overall.

I bought HCM 12 years ago and till hold it (look at the % gain). I also bought Tesla jsut over 2 years ago and still hold it. I have numerous other examples.

Hold if you believe in the Company and you will be very well rewarded...........and remember Biotech is a long term investment

"Does anyone have a recommendation of a platform to buy TLSA shares since neither Barclays nor H/L will deal in them."

AJ Bell although exchange fees will be too high unless you trade significant sized deals

snap MOG, unbelievable volume here

Average daily volume 390,000
Todays's first 40 min volume 3.5 million

https://www.share-talk.com/share-talk-bulletin-board-heroes-wednesday-13th-january-2021/#gs.qi11fj

The critical point for me is that Regeneron has grown into the world's leading antibody Company. Doctor Graham is enthused about Foralumab but there may be some other reason for his appointment.

It's worth looking at Regeneron's antibody pipeline and seeing if you can spot a gap, a hole that could be filled - cue FORALUMAB

yes and I am one (in an American firm) but its's also worth considering that prior to acquisition, big pharma will often put a senior clinician or development person into the firm or asset owner they may acquire. It happens very often, so we could see some form of deal with Regeneron here. The Company is the world's leader in Antibodies.

yes, or a strategic short-term appointment by Tiziana and a potential acquirer :o-)

The appointment of a Chief Medical Officer is a great step forward and signals the Company's intentions to step up its comms within the medical community. Is this a further sign they want to push the pipeline even faster?

"He has in depth Global Development Expertise (e.g. Virology, Respiratory, Dermatology, Allergy, & Rheumatology) in early & late stage Clinical Development and in Medical Affairs, with a strong track record for Developing and Accelerating Phase I-IV programs. Multiple IND's, NDA/BLA filings and/or defense and multiple successful launches."

2020 sales of Covid-19 therapies firm up

https://www.evaluate.com/vantage/articles/news/snippets/2020-sales-covid-19-therapies-firm?mkt_tok=eyJpIjoiTlRRM1lqVXlNemcwTmpZMyIsInQiOiIxbzRQeWx5b0xLM0JZRTQzMXljTEozbHh4ZzAwY0V4ZGJ0Q2d1TU9IdW9VbktcL29jek1WNVI1VDZcL2EyUUE2OVdLZ21cL0NXZm1NaFNxQUxyUGtLbEVIUFArb0pqXC94NERPTmFvTDVlNW13RFNTM3lMcWFOWm02aGRrbkpyYXlFM2UifQ%3D%3D

"The logistical problems of administering these infused therapies to pre-hospitalised patients has limited their usefulness; "

Tiziana can address this issue with Foralumab and needs to get the word out in the Biotech world

I am amazed it's not been taken out already - even $1 billion is small change for Big Pharma

there is no technical resistance to 200p+

https://www.share-talk.com/share-talk-bulletin-board-heroes-tuesday-12th-january-2021/#gs.qevhrn

If you look at Kymab's pipeline, then compare it to Tiziana's, you will see the latters is bigger and at a later stage, so I agree with your assertion that Tiziana is worth more as a Company, if someone thinks the assets are worth it.

http://www.tizianalifesciences.com/cms/resources/tlsa-non-confidential-jan-2021.pdf

This latest Deck is a vast improvement, very professional, and has all the elements that specialist Biotech Investors look for, upcoming catalysts, a lot of technical data and sets out the Company's growth and next steps.